Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
185.6 GBX | -0.43% | +0.43% | +9.43% |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
Mar. 19 | Essentra makes profit but revenue declines, CFO plans to retire | AN |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Industrial Machinery & Equipment
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.43% | 674M | B | ||
+21.92% | 9.07B | B+ | ||
+26.24% | 6.62B | - | C+ | |
+13.41% | 5B | C+ | ||
+10.17% | 4.91B | C | ||
+25.71% | 4.3B | A- | ||
-21.79% | 2.94B | - | ||
-3.49% | 2.67B | D | ||
-0.85% | 2.56B | A- | ||
-27.82% | 2.56B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ESNT Stock
- Ratings Essentra plc